首页> 外文OA文献 >Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial

【2h】

Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial

机译：鉴定新的基因型截止水平，以预测罗非韦/丽凡昔（Darunavir / Ritonavir在泰坦审判中的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A Hill; A-G Marcelin; V Calvez;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. [J] . HIV medicine . 2009,第10期

机译：在TITAN试验中确定新的基因型临界水平，以预测洛匹那韦/利托那韦和达那韦/利托那韦的疗效。
2. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. [J] . Madruga JV, Berger D, McMurchie M, The Lancet . 2007,第9581期

机译：在TITAN中，经过治疗，HIV感染的患者在48周时，达那那韦-利托那韦和洛匹那韦-利托那韦的疗效和安全性比较：一项随机对照III期试验。
3. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial [J] . Santos Jose R., Llibre Josep M., Bravo Isabel, AIDS Research and Human Retroviruses . 2016,第5期

机译：简短交流：简化使用洛匹那韦/利托那韦或达鲁那韦/利托那韦单药治疗的疗效和安全性：一项随机临床试验
4. A pharmacokinetic model of lopinavir in combination with ritonavir in human [C] . Duangchaemkarn Khanita, Reisfeld Brad, Lohitnavy Manupat Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2014

机译：洛匹那韦联合利托那韦在人体内的药代动力学模型
5. Validation of a UPLC-MS/MS method for the simultaneous measurement of the antiretroviral drugs atazanavir, darunavir, efavirenz, etravirine, lopinavir, raltegravir, ritonavir from human plasma. [D] . Patel, Rutva. 2012

机译：用于从人血浆中同时测定抗逆转录病毒药物阿扎那韦，达鲁那韦，依非韦伦，依曲韦林，洛匹那韦，拉格列韦，利托那韦的UPLC-MS / MS方法的验证。
6. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients [O] . Nicola Gianotti, Alessandro Cozzi-Lepri, Andrea Antinori, -1

机译：在HIV感染的病毒学抑制患者中选择安全的lopinavir / ritonavir或darunavir / ritonavir单一疗法的候选药物的完善标准
7. IN2 Comparative Efficacy at 48 Weeks of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Treatment Naive Hiv-1 Patients: A Matching Adjusted Indirect Comparison of Randomized Trials [O] . Xie J., Juday T., Swallow E., 2012

机译：Atazanavir / Ritonavir与Darunavir / Ritonavir在48周治疗纯净Hiv-1患者中的IN2疗效比较：随机试验的匹配调整间接比较

Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial

著录项

引文网络

相似文献

相关主题

期刊订阅